Insulin glargine
Accession Number
DB00047  (BTD00045, BIOD00045, DB01308)
Biologic Classification
Protein Based Therapies
Hormones / Insulins

Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis.

Insulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glargine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after several oral medications such as Metformin, Gliclazide, or Sitagliptin have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.

Marketed as the brand name product Lantus, insulin glargine has a duration of action up to 24 hours allowing for once-daily dosing, typically at bedtime. Due to its duration of action, Lantus is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Basal insulin is often combined with short-acting "bolus insulin" such as Insulin Lispro, Insulin Glulisine, and Insulin Aspart to provide higher doses of insulin that are required following meals. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.

Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from endogenous human insulin by the replacement of an asparagine residue at position A21 of the A-chain with glycine and addition of two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4 allowing for the slow release of small amounts of insulin glargine, giving the drug a long duration of action and no pronounced peak concentration.

Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.

Protein structure
Protein chemical formula
Protein average weight
6063.0 Da
>A chain
>B chain
Download FASTA Format
  • Insulin glargine
  • Insulin Glargine (rDNA origin)
  • Insulin glargine recombinant
  • Insulina glargina
External IDs
HOE 71GT / HOE 901 / LY 2963016 / MK-1293
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbasaglarInjection, solution100 Units/mlSubcutaneousEli Lilly Nederland B.V.2014-09-09Not applicableEu
AbasaglarInjection, solution100 Units/mlSubcutaneousEli Lilly Nederland B.V.2014-09-09Not applicableEu
AbasaglarInjection, solution100 Units/mlSubcutaneousEli Lilly Nederland B.V.2014-09-09Not applicableEu
AbasaglarInjection, solution100 Units/mlSubcutaneousEli Lilly Nederland B.V.2014-09-09Not applicableEu
AbasaglarInjection, solution100 Units/mlSubcutaneousEli Lilly Nederland B.V.2014-09-09Not applicableEu
AbasaglarInjection, solution100 Units/mlSubcutaneousEli Lilly Nederland B.V.2014-09-09Not applicableEu
AbasaglarInjection, solution100 Units/mlSubcutaneousEli Lilly Nederland B.V.2014-09-09Not applicableEu
AbasaglarInjection, solution100 Units/mlSubcutaneousEli Lilly Nederland B.V.2014-09-09Not applicableEu
AbasaglarInjection, solution100 Units/mlSubcutaneousEli Lilly Nederland B.V.2014-09-09Not applicableEu
AbasaglarInjection, solution100 Units/mlSubcutaneousEli Lilly Nederland B.V.2014-09-09Not applicableEu
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Soliqua 100/33Insulin glargine (100 U/1mL) + Lixisenatide (33 ug/1mL)Injection, solutionSubcutaneousSanofi Aventis2016-11-21Not applicableUs
International/Other Brands
Basaglar / Lantus OptiSet / Lantus R / Lantus Solostar / Lusduna Nexvue / Optisulin / Toujeo / Toujeo Solostar
CAS number



Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Associated Conditions

Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, the pancreas produces a continuous supply of low levels of basal insulin along with spikes of insulin following meals. Increased insulin secretion following meals is responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). Insulin glargine is a long-acting insulin analogue with a flat and predictable action profile. It is used to mimic the basal levels of insulin in diabetic individuals.

Mechanism of action

Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body.

AInsulin receptor

Because of the modifications to the A and B chain, the isoelectric point shifts towards a neutral pH and insulin glargine is more stable in acidic conditions than regular insulin. As insulin glargine is less soluble at neutral pH, once injected, forms microprecipitates. Slow release of insulin glargine from microprecipitates provides a relatively constant concentration of insulin over 24 hours. Onset of action is approximately 1.1 hours.

The pharmacokinetic profiles for single 0.4, 0.6, and 0.9 U/kg doses of Toujeo in 24 patients with type 1 diabetes mellitus was evaluated in a euglycemic clamp study. The median time to maximum serum insulin concentration was 12 (8–14), 12 (12–18), and 16 (12–20) hours, respectively. Steady-state insulin concentrations are reached by at least 5 days of once-daily subcutaneous administration of 0.4 U/kg to 0.6 U/kg doses of Toujeo over 8 days in patients with type 1 diabetes mellitus.

The median time to maximum effect of Basaglar (measured by the peak rate of glucose infusion) was approximately 12.0 hours. The pharmacodynamic profile of Basaglar following subcutaneous injection demonstrated sustained glucose lowering activity over 24 hours with no pronounced peak. The mean area under the glucose infusion rate curves (measure of overall pharmacodynamic effect) and maximum glucose infusion rate were 1670 mg/kg and 2.12 mg/kg/min, respectively. On average, serum insulin concentrations declined to baseline by approximately 24 hours.

Volume of distribution
Not Available
Protein binding
Not Available

Insulin glargine is metabolized in the liver into two active metabolites with similar activity to insulin: 21a-Gly-human insulin (M1) and 21a-Gly-des-30b- threonine insulin (M2), with M1 being the predominant metabolite.

Route of elimination
Not Available
Half life
Not Available
Not Available

Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. Other adverse events that may occur include allergic reaction, injection site reaction, lipodystrophy, pruritis, and rash.

Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
2,4-thiazolidinedioneThe risk or severity of hypoglycemia can be increased when Insulin glargine is combined with 2,4-thiazolidinedione.
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Insulin glargine can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
AcarboseThe risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Acarbose.
AcebutololAcebutolol may increase the hypoglycemic activities of Insulin glargine.
AcetazolamideThe therapeutic efficacy of Insulin glargine can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Acetohexamide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Insulin glargine can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Insulin glargine.
AgmatineThe risk or severity of hypoglycemia can be increased when Agmatine is combined with Insulin glargine.
AICA ribonucleotideThe risk or severity of hypoglycemia can be increased when Insulin glargine is combined with AICA ribonucleotide.
Food Interactions
Not Available


General References
  1. Chatterjee S, Tringham JR, Davies MJ: Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus. Expert Opin Pharmacother. 2006 Jul;7(10):1357-71. [PubMed:16805721]
  2. Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ: Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs. 2003;63(16):1743-78. [PubMed:12904090]
  3. Home PD, Ashwell SG: An overview of insulin glargine. Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S57-63. [PubMed:12324987]
  4. Jones R: Insulin glargine (Aventis Pharma). IDrugs. 2000 Sep;3(9):1081-7. [PubMed:16049868]
  5. Wang F, Carabino JM, Vergara CM: Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. [PubMed:12860485]
  6. Warren E, Weatherley-Jones E, Chilcott J, Beverley C: Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 2004 Nov;8(45):iii, 1-57. [PubMed:15525480]
  7. Owens DR, Bolli GB: Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. 2008 Oct;10(5):333-49. doi: 10.1089/dia.2008.0023. [PubMed:18715209]
  8. Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S: The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016 Sep;32(6):478-96. doi: 10.1002/dmrr.2763. Epub 2015 Nov 25. [PubMed:26509843]
  9. Leto D, Saltiel AR: Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol. 2012 May 23;13(6):383-96. doi: 10.1038/nrm3351. [PubMed:22617471]
External Links
PubChem Substance
Therapeutic Targets Database
RxList Drug Page Drug Page
ATC Codes
A10AE04 — Insulin glargine
AHFS Codes
  • 68:20.08 — Insulins
FDA label
Download (51.2 KB)

Clinical Trials

Clinical Trials
0RecruitingPreventionRetinopathy, Diabetic1
0RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
1CompletedNot AvailableDiabetes Mellitus (DM)1
1CompletedNot AvailableDiabetes, Diabetes Mellitus Type 12
1CompletedBasic ScienceDiabetes, Diabetes Mellitus Type 14
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceType 2 Diabetes Mellitus3
1CompletedTreatmentDelivery Systems / Diabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
1CompletedTreatmentDiabetes Mellitus (DM)2
1CompletedTreatmentDiabetes Mellitus (DM) / Diabetes, Diabetes Mellitus Type 19
1CompletedTreatmentDiabetes Mellitus (DM) / Diabetes, Diabetes Mellitus Type 1 / Healthy Volunteers2
1CompletedTreatmentDiabetes Mellitus (DM) / Diabetes, Diabetes Mellitus Type 1 / Type 2 Diabetes Mellitus1
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers2
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers / Type 2 Diabetes Mellitus2
1CompletedTreatmentDiabetes Mellitus (DM) / Hyperglycemias1
1CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus3
1CompletedTreatmentDiabetes, Diabetes Mellitus Type 15
1CompletedTreatmentType 2 Diabetes Mellitus5
1RecruitingBasic ScienceHealthy Volunteers1
1TerminatedBasic ScienceHealthy Volunteers1
2CompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentDiabetes Mellitus (DM) / Diabetes, Diabetes Mellitus Type 11
2CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus3
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 13
2CompletedTreatmentNonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis / Type 2 Diabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus6
2RecruitingTreatmentDiabetes Mellitus (DM)1
2RecruitingTreatmentType 2 Diabetes Mellitus1
2TerminatedTreatmentType 2 Diabetes Mellitus1
2, 3CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
3Active Not RecruitingTreatmentComparative Effectiveness of Glycemia-lowering Medications / Type 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 12
3Active Not RecruitingTreatmentType 1 Diabetes Mellitus-Type 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentType 2 Diabetes Mellitus6
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Pressure (Hypertension) / High Cholesterol / Type 2 Diabetes Mellitus1
3CompletedTreatmentCardiovascular Disease (CVD) / Hyperglycemias / Myocardial Infarction1
3CompletedTreatmentChronic Kidney Disease (CKD) / Type 2 Diabetes Mellitus1
3CompletedTreatmentDawn Phenomenon / Diabetes, Diabetes Mellitus Type 11
3CompletedTreatmentDiabetes Mellitus (DM)4
3CompletedTreatmentDiabetes Mellitus (DM) / Diabetes, Diabetes Mellitus Type 16
3CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus28
3CompletedTreatmentDiabetes Mellitus, Insulin-Dependent1
3CompletedTreatmentDiabetes Mellitus, Non-Insulin-Dependent1
3CompletedTreatmentDiabetes, Diabetes Mellitus Type 113
3CompletedTreatmentPoor Glycemic Control1
3CompletedTreatmentType 2 Diabetes Mellitus61
3Not Yet RecruitingTreatmentType 2 Diabetes Mellitus2
3RecruitingTreatmentDiabetes, Diabetes Mellitus Type 13
3RecruitingTreatmentHyperglycemias / Stroke, Acute1
3RecruitingTreatmentType 2 Diabetes Mellitus7
3TerminatedTreatmentDiabetes, Diabetes Mellitus Type 11
3TerminatedTreatmentLeukemias / Malignant Lymphomas1
3TerminatedTreatmentType 2 Diabetes Mellitus3
3Unknown StatusTreatmentCystic Fibrosis (CF) / Glucose tolerance impaired1
3Unknown StatusTreatmentType I Diabetes1
3WithdrawnSupportive CareHyperglycemias / Leukemias1
3WithdrawnTreatmentType 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
4Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 1 / Nocturnal Hypoglycemia / Recurrent Severe Hypoglycaemia1
4Active Not RecruitingTreatmentType2 Diabetes1
4CompletedNot AvailableType 2 Diabetes Mellitus1
4CompletedBasic ScienceType 2 Diabetes Mellitus1
4CompletedPreventionCoronary Artery Disease1
4CompletedScreeningDiabetes Mellitus (DM)1
4CompletedTreatmentAcute Myocardial Infarction (AMI) / Type 2 Diabetes Mellitus1
4CompletedTreatmentCardiovascular Disease (CVD) / Endothelial Dysfunction / Type 2 Diabetes Mellitus1
4CompletedTreatmentCongestive Heart Failure (CHF) / Type 2 Diabetes Mellitus1
4CompletedTreatmentDiabetes Mellitus (DM)12
4CompletedTreatmentDiabetes Mellitus (DM) / Diabetes, Diabetes Mellitus Type 11
4CompletedTreatmentDiabetes Mellitus (DM) / General Surgery1
4CompletedTreatmentDiabetes Mellitus (DM) / Hyperglycemias2
4CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus6
4CompletedTreatmentDiabetes, Diabetes Mellitus Type 110
4CompletedTreatmentHospitalization / Hyperglycemias / Type 2 Diabetes Mellitus1
4CompletedTreatmentHyperglycemias / Type 2 Diabetes Mellitus1
4CompletedTreatmentHypoglycemia / Type 2 Diabetes Mellitus1
4CompletedTreatmentImpaired Renal Function / Type 2 Diabetes Mellitus1
4CompletedTreatmentInpatient Hyperglycemia / Type 2 Diabetes Mellitus1
4CompletedTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD)1
4CompletedTreatmentSecondary Drug Failure / Type 2 Diabetes Mellitus1
4CompletedTreatmentType 2 Diabetes Mellitus74
4Enrolling by InvitationTreatmentDiabetes, Diabetes Mellitus Type 11
4Not Yet RecruitingTreatmentType 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentType2 Diabetes1
4Not Yet RecruitingTreatmentType2 Diabetes Mellitus1
4RecruitingHealth Services ResearchType 2 Diabetes Mellitus1
4RecruitingTreatmentDiabetes, Diabetes Mellitus Type 12
4RecruitingTreatmentDiabetes, Diabetes Mellitus Type 1 / Ketoacidosis, Diabetic1
4RecruitingTreatmentHyperglycaemia (Diabetic) / Overweight and Obesity / Type 2 Diabetes Patients1
4RecruitingTreatmentHyperglycemia Steroid-induced / Insulin Resistance, Diabetes1
4RecruitingTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD) / Type 2 Diabetes Mellitus1
4RecruitingTreatmentType 2 Diabetes Mellitus7
4TerminatedTreatmentDiabetes Mellitus (DM)1
4TerminatedTreatmentDiabetes, Diabetes Mellitus Type 11
4TerminatedTreatmentPost-Transplant Glucocorticoid Induced Diabetes1
4TerminatedTreatmentType 2 Diabetes Mellitus7
4Unknown StatusPreventionType 2 Diabetes Mellitus1
4Unknown StatusTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus1
4Unknown StatusTreatmentDiabetes Mellitus (DM)1
4Unknown StatusTreatmentDiabetes, Diabetes Mellitus Type 12
4Unknown StatusTreatmentInsulin-requiring Type 2 Diabetes Mellitus1
4Unknown StatusTreatmentLiver Cirrhosis / Type 2 Diabetes Mellitus1
4Unknown StatusTreatmentType 2 Diabetes Mellitus1
4WithdrawnTreatmentType 2 Diabetes Mellitus1
Not AvailableActive Not RecruitingNot AvailableDiabetes Mellitus (DM)1
Not AvailableCompletedNot AvailableBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableDiabetes Mellitus (DM)1
Not AvailableCompletedBasic ScienceDiabetes Mellitus (DM)1
Not AvailableCompletedOtherDiabetes Mellitus (DM)1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM)3
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Hyperglycemias1
Not AvailableCompletedTreatmentDiabetes, Diabetes Mellitus Type 11
Not AvailableCompletedTreatmentDiabetic Peripheral Neuropathy (DPN) / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentKetoacidosis, Diabetic1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus6
Not AvailableRecruitingNot AvailableDiabetes Mellitus (DM)1
Not AvailableRecruitingTreatmentDiabetes, Diabetes Mellitus Type 1 / Ketoacidosis, Diabetic1
Not AvailableRecruitingTreatmentType 2 Diabetes Mellitus2
Not AvailableTerminatedTreatmentDiabetes, Diabetes Mellitus Type 11
Not AvailableUnknown StatusPreventionPre-Diabetic1
Not AvailableUnknown StatusTreatmentDiabetes, Diabetes Mellitus Type 1 / Hypoglycemia1
Not AvailableWithdrawnTreatmentType 2 Diabetes Mellitus1


  • Sanofi aventis us llc
  • Gruppo Lepetit SPA
  • Physicians Total Care Inc.
  • Sanofi-Aventis Inc.
Dosage forms
Injection, solutionSubcutaneous100 Units/ml
Injection, solutionSubcutaneous100 [iU]/1mL
SolutionSubcutaneous100 unit
Injection, solutionSubcutaneous
Injection, solutionSubcutaneous300 U/1mL
Injection, solutionSubcutaneous300 units/ml
SolutionSubcutaneous300 unit
Unit descriptionCostUnit
Lantus SoloStar 100 unit/ml Solution 1 Box = Five 3ml Syringes223.89USD box
Lantus 100 unit/ml Solution 10ml Vial111.88USD vial
Lantus for OptiClik 100 unit/ml Solution 3ml Cartridge44.78USD cartridge
Lantus 100 unit/ml cartridge14.35USD ml
Lantus solostar 100 unit/ml14.35USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)


Experimental Properties
melting point (°C)81 °CKhachidze, D.G. et al., J. Biol. Phys. Chem. 1:64-67 (2001)
hydrophobicity0.098Not Available
isoelectric point6.88Not Available


Not Available
Organic Compounds
Super Class
Organic Acids
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Alternative Parents
Not Available
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available


Pharmacological action
General Function
Receptor signaling protein tyrosine kinase activity
Specific Function
Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (...
Gene Name
Uniprot ID
Uniprot Name
Insulin receptor
Molecular Weight
156331.465 Da
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Le Roith D: Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev. 2007 Nov;23(8):593-9. [PubMed:17922476]
  3. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R: Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia. 2010 Aug;53(8):1743-53. doi: 10.1007/s00125-010-1760-6. Epub 2010 Apr 28. [PubMed:20424816]
  4. Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T: Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Diabetes Res Clin Pract. 2008 Sep;81(3):269-77. doi: 10.1016/j.diabres.2008.05.007. Epub 2008 Jun 27. [PubMed:18585815]

Drug created on June 13, 2005 07:24 / Updated on February 18, 2019 20:24